ReviewNature reviews. Cardiology2011
Current challenges in the clinical management of hypertension.
Review in Nature reviews. Cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03887416 (Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Pooled it
- General practice and ethnicity: an experimental study of doctoring.BMC family practice · 2014Trial
- The higher dietary energy-to-fiber ratio is associated with an increased risk of poor blood pressure control among patients with essential hypertension: a cross-sectional study.Frontiers in nutrition · 2026Article
- Effectiveness of hierarchical medical system policy: an interrupted time series analysis of a pilot scheme in China.Health policy and planning · 2023Article
- An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk.Frontiers in physiology · 2021Review
- The use of antihypertensive fixed combinations in clinical practice needs a reappraisal.Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
- Sacubitril/valsartan in the treatment of arterial hypertension: an unaccomplished promise?Hypertension research : official journal of the Japanese Society of Hypertension · 2017Article
- Traditional Chinese medicine suppresses left ventricular hypertrophy by targeting extracellular signal-regulated kinases signaling pathway in spontaneously hypertensive rats.Scientific reports · 2017Article
- New Strategy to Control Blood Pressure: Interactive Mobile Phone Support.Journal of clinical hypertension (Greenwich, Conn.) · 2016Article
- Renin-angiotensin system blockade: time for a reappraisal?European heart journal · 2014Article
- Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2014Review
- Physician underutilization of effective medications for resistant hypertension at office visits in the United States: NAMCS 2006-2010.Journal of general internal medicine · 2014Article
- Estimate of nocturnal blood pressure and detection of non-dippers based on clinical or ambulatory monitoring in the inpatient setting.BMC cardiovascular disorders · 2013Article
- How can resistant hypertension be identified and prevented?Nature reviews. Cardiology · 2013Review
- Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2012Article
- Azilsartan medoxomil: a review of its use in hypertension.Clinical drug investigation · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated blood pressure (BP) is probably the most-important modifiable risk factor for cardiovascular disease (CVD). BP influences the development of CVD, even if levels of BP are well below the usual cut-off point that defines the presence of arterial hypertension. Adequate measurement of BP is the most-important requirement for the diagnosis and treatment of patients with suspected hypertension. The use of methodologies such as ambulatory and home BP monitoring have become powerful tools for defining the 'real' BP of patients, discarding the white-coat effect, and discovering masked hypertension. Early intervention with life-style changes and antihypertensive drugs is required to obtain the best outcome for the patient. In this sense, early use of combination antihypertensive drug therapy is recommended. The treatment of resistant hypertension-the type of elevated BP that is most difficult to control-has clearly improved over the past decade. Further studies are required to define how antihypertensive therapy should be used in the earliest stages of hypertension and for the treatment of patients with a mild-to-moderate increase in global cardiovascular risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.